Cellectis S.A. Stock News

Cellectis S.A. (NASDAQ:CLLS ) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Mark Frat

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform

NEW YORK, 28 sept. 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de gén

Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday. Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares climbed 46.4% to close at $0.3750 on Friday.

Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day ex

Gainers HHG Capital Corporation (NASDAQ: HHGC) shares rose 42.1% to $14.56 in pre-market trading. Rubius Therapeutics, Inc. (NASDAQ: RUBY) rose 32% to $0.60 in pre-market trading after declining 7% o

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, 01 sept. 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de gén

NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platfor

NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)